Literature DB >> 21740895

Effect of sample dilution on serum free light chain concentration by immunonephelometric assay.

Martine Vercammen1, Patricia Meirlaen, Linda Broodtaerts, Isabelle Vande Broek, Xavier Bossuyt.   

Abstract

BACKGROUND: Free light chains (FLC) are useful biomarkers in the assessment of plasma cell disorders. Concerns have been raised about some technical aspects of the assay. This report examined the occurrence of dilution anomalies and/or antigen excess.
METHODS: FLC were determined on a BNII instrument at at-least two dilutions (100- and 2000-fold) in 2088 consecutive samples from 865 different patients. In part of them, the 400-fold dilution was also available.
RESULTS: Higher than 2-fold differences and inconsistencies ["<" or ">" result at one dilution not consistent with the result obtained at another dilution] between the 100- and 2000-fold dilutions were found in 12.7% of patients for κ FLC and in 3.1% of patients for λ FLC. More than 4-fold differences between results obtained at the 2000-fold and the 100-fold dilutions were observed in 5.4% of patients for κ FLC and in 1.2% of patients for λ FLC.
CONCLUSIONS: The FLC assay on BNII suffers from sample dilution anomalies and/or failure of antigen excess detection in a substantial fraction of patients. Laboratory professionals and clinicians should be alert to such analytical difficulties.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21740895     DOI: 10.1016/j.cca.2011.06.021

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Serum free light chain quantitative assays: Dilemma of a biomarker.

Authors:  Giovanni Cigliana; Francesca Gulli; Cecilia Napodano; Krizia Pocino; Elena De Santis; Luigi Colacicco; Iole Cordone; Laura Conti; Umberto Basile
Journal:  J Clin Lab Anal       Date:  2017-04-26       Impact factor: 2.352

2.  Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma.

Authors:  S H K Murng; L Follows; P Whitfield; J A Snowden; K Swallow; K Green; R Sargur; W Egner
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

3.  The analytical performance evaluation of Freelite™ Human Kappa Free and Human Lambda Free on the SPAPLUS™ immunoturbidimetric analyzer.

Authors:  Kyong-Ho Cha; Yang Bo Sim; Hyojin Chae; Hae-il Park; Myungshin Kim; Yonggoo Kim
Journal:  J Clin Lab Anal       Date:  2014-01-29       Impact factor: 2.352

4.  Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?

Authors:  Judith A Brebner; Robert A Stockley
Journal:  F1000 Med Rep       Date:  2013-02-01

5.  Evaluation of a new ELISA assay for monoclonal free-light chain detection in patients with cardiac amyloidosis.

Authors:  Hajer Abroud; Asma Beldi-Ferchiou; Vincent Audard; François Lemonnier; Fabien Le Bras; Karim Belhadj; Anissa Moktefi; Elsa Poullot; Khalil El Karoui; Jehan Dupuis; Alizée Maarek; Louise Roulin; Marie-Hélène Delfau-Larue; Silvia Oghina; Mounira Kharoubi; Mélanie Bézard; Amira Zaroui; Thibaud Damy; Valérie Molinier-Frenkel
Journal:  EJHaem       Date:  2022-06-24

6.  Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy.

Authors:  Han-Sung Kim; Hyun Soo Kim; Kyu-Sung Shin; Wonkeun Song; Hyo Jung Kim; Hyeong Su Kim; Min-Jeong Park
Journal:  Biomed Res Int       Date:  2014-05-27       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.